Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 12.51 as of 2026-09-10T14:30:33.000Z.
Consensus retrieved: 2026-09-10T03:43:59.460Z. This records retrieval, including cache reads, rather than vendor publication. A quote earlier than this retrieval cannot support current forward valuation.
Quote observation: 2026-09-10T14:30:33.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: af83445863c5cbd0ce920ec438e85bb38c520832abb93cce62fb5a9f53d58986
Forward PE Ratio (12.51) = Close Price ($89.56) / Consensus Forward EPS ($7.16)
FORWARD PE RATIO
12.51
SECTOR MEDIAN · HEALTHCARE
19.05
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
-34.35%
vs the sector median at left
Solventum Corporation
Market Cap
$15.51B
Forward PE Ratio
12.51
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Solventum Corporation (SOLV) | $15.51B | 12.51 |
| Medpace Holdings, Inc. (MEDP)vs › | $16.27B | 33.12 |
| Exelixis, Inc. (EXEL)vs › | $14.56B | 16.49 |
| Revvity, Inc. (RVTY)vs › | $13.61B | 22.79 |
| Charles River Laboratories International, Inc. (CRL)vs › | $13.19B | 24.19 |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $18.02B | 10.92 |
| Penumbra, Inc. (PEN)vs › | $12.57B | 67.79 |
| Baxter International Inc. (BAX)vs › | $12.54B | 11.81 |
| Viatris Inc. (VTRS)vs › | $18.90B | 6.49 |
| Encompass Health Corporation (EHC)vs › | $12.08B | 19.92 |
Trailing P/E
10.9
reported TTM EPS
Forward P/E
12.5
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $7.16 implies -12.6% EPS decline vs the reported trailing $8.19.
At today's $89.56 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $7.16 | $7.07 – $7.49 | 9 | 12.5x |
| 2027-12-31 | $7.30 | $6.59 – $7.65 | 9 | 12.3x |
| 2028-12-31 | $8.10 | $4.14 – $10.48 | 6 | 11.1x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
